2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
264
Other hematologic neoplasm
146
Dermatologic
115
Plasma cell
73
Myeloid
60
Sarcoma
47
CNS
18
Classical hematology
16
Genitourinary
11
Other neoplasm
10
Gastrointestinal
10
Gynecologic
6
Breast
6
Thoracic
5
Head & Neck
3
Endocrine
1
Conditions
Neuroendocrine Tumors
532
Pituitary Neoplasms
188
Multiple Endocrine Neoplasia Type 1
187
Thyroid Cancer, Papillary
178
Pheochromocytoma
153
Carcinoma, Neuroendocrine
140
Thyroid Neoplasms
130
Neoplasms
107
Paraganglioma
99
Carcinoid Tumor
99
Adrenocortical Carcinoma
92
Thyroid Carcinoma, Anaplastic
82
Pancreatic Neoplasms
69
Neoplasm Metastasis
67
Insulinoma
61
Adrenal Gland Neoplasms
61
Carcinoma, Medullary
59
Gastro-enteropancreatic neuroendocrine tumor
58
Adenocarcinoma, Follicular
58
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
56
Adenoma, Islet Cell
56
Lung Neoplasms
50
Sarcoma
49
Colorectal Neoplasms
49
Carcinoma, Renal Cell
49
Melanoma
47
Small Cell Lung Carcinoma
45
Prostatic Neoplasms
44
Head and Neck Neoplasms
43
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Extranodal NK-T-Cell
×
Endocrine
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled